Plato BioPharma, Inc (“PBI”) announced today that its Board of Directors has appointed a new director, Mr. Dan Mitchell, effective November 1, 2010. Dan has been in the venture capital industry for over 25 years focused on early stage opportunities primarily in healthcare and biotech industries. Dan also serves on the Boards of Directors of Kalypto Medican, GlobeImmune, and Apoplogic.
“Dan is an outstanding addition to the Plato BioPharma Board,” said Craig F. Plato, CEO and founder of Plato BioPharma. “His substantial experience and financial background will serve both our shareholders and customers well as PBI continues to grow and expand its capabilities and offerings.”
Dan began his venture career at the First National Bank of Chicago’s Institutional Venture Capital Fund, and then co-founded Capital Health Venture Partners, a healthcare-focused venture fund in 1985. In 1996 he co-founded Sequel Venture Partners (“Sequel”). Sequel invests in seed and early stage opportunities primarily in the Front Range of Colorado. His prior investments include Pyxis (acq. by Cardinal Health), Genomic Solutions (acq. by Harvard Bioscience), Tetra Technologies (NYSE: TTI), Quovadx (NASDAQ: QVDX), and Myogen (acq. by Gilead Sciences, Inc).
Founded in 2009, Plato BioPharma, Inc is a leading provider of pre-clinical drug discovery contract research organization (CRO). PBI offers expert in vivo capabilities in cardiovascular, renal, pulmonary, and hepatic systems from pharmacokinetics through proof-of-concept studies.